SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Zirdu who wrote (3794)2/10/1998 2:22:00 PM
From: tommysdad  Read Replies (1) of 6136
 
<<Maybe, because of
it's small molecular size and less "extraneous" material, for example, the "Crix belly" and "buffalo hump"
problems will not be a side effect of Viracept, or maybe it will cause less severe effects.>>

Huh? Crixivan is C36H47N5O4-H2O4S. Viracept is C32H45N3O4S-CH4O3S. Not a big diffrence in "molecular size" there. Neither is a particularly small molecule -- that term is usually reserved for molecules with molecular weights less than 400-500, and both Viracept and Crixivan beat that by a lot.

There is nothing about the molecular structure of these molecules that would have anticipated this problem. It is certainly safe to assume that the "buffalo hump" effect will be different for the various PI's, but that difference will have to come from empirical observations in the clinic rather than guesses from molecular structure.

Just curious: what part of either molecule do you consider to be "extraneous"?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News